Hypofibrinogenemia Market

The market size of Hypofibrinogenemia in the 7MM was USD 161.5 Million in 2017, which is expected to increase further during the forecast period 2017-2030.

In 2017, the total prevalent population of Hypofibrinogenemia in the 7MM was 11,084. The prevalent population of Hypofibrinogenemia in Spain was found to be 493.

Some of the key companies involved in developing therapies for Hypofibrinogenemia includes Biotest, CSL Behring, Octapharma, LFB Biomedicaments and many others.

For more detailed information on Hypofibrinogenemia market, visit: https://www.delveinsight.com/report-store/hypofibrinogenemia-market